Evidence map›Paper›PMID 41787256›Full record

ArticleClinical proteomics2026

IL3RA identified as novel biomarker and therapeutic target for ER

Heting Mei, Zehan Zhang, Nan Jiang, Wenping Lu, Lei Chang, Qingya Song, Feng Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical proteomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Heting Mei *Department of Oncology, China Academy of Chinese Medical Sciences Guang'anmen Hospital, Beijing, China.
Zehan Zhang *School of traditional Chinese medicine, Beijing University of Chinese Medicine, Beijing, China.
Nan Jiang *Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Wenping LuDepartment of Oncology, China Academy of Chinese Medical Sciences Guang'anmen Hospital, Beijing, China. lu_wenping@sina.com.
Lei ChangDepartment of Oncology, China Academy of Chinese Medical Sciences Guang'anmen Hospital, Beijing, China.
Qingya SongDepartment of Oncology, China Academy of Chinese Medical Sciences Guang'anmen Hospital, Beijing, China.
Feng LiSchool of traditional Chinese medicine, Beijing University of Chinese Medicine, Beijing, China. lifeng_bucm0610@126.com.

Funding

National Natural Science Foundation of China 81973839
6 · The paper itself

Abstract

backgroundEstrogen receptor-positive (ER

methodsUsing two-sample Mendelian randomization (TSMR) and Bayesian colocalization, we analyzed associations between plasma protein quantitative trait loci from deCODE/Fenland cohorts and ER

resultsTSMR identified 38 causal plasma proteins (deCODE), with Bayesian analysis prioritizing 12 candidates. IL3RA emerged as stable and novel protective factor, validated in Fenland data. TCGA revealed reduced IL3RA expression in ER

conclusionsOur study identified IL3RA as novel biomarker and therapeutic target for ER

Indexed as

ER+ breast cancerIL3RAProteome-wide Mendelian randomization

Identifiers

PMID41787256
PMCPMC13072662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.